762P Personalized immunotherapy with encapsulated cell technology: Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors

Abstract

Listen

Translate article

Preclinical data shows that sustained, local delivery of low doses of GM-CSF by irradiated, genetically engineered tumor cells at the immunization site leads to specific, long-lasting anti-tumor immunity in several tumor types. Providing sustained levels of GM-CSF SC in a clinical setting remains challenging. Encapsulated Cell Technology enables the sustained and controlled delivery of GM-CSF by allogeneic cells. MVX-ONCO is an active, personalized cancer immunotherapy combining irradiated autologous tumor cells and encapsulated, genetically engineered allogeneic cells producing GM-CSF.